We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Gilead Sciences (GILD - Free Report) is expected to reveal quarterly loss of -$7.07 per share, indicating a decline of 451.7% compared to the year-ago period. Analysts forecast revenues of $7.37 billion, representing an increase of 4% year over year.
The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Gilead metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Product Sales- HIV- Genvoya- Total' to come in at $294.52 million. The estimate indicates a change of -21.9% from the prior-year quarter.
The consensus estimate for 'Product Sales- HIV- Descovy- Total' stands at $749.57 million. The estimate points to a change of +14.8% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Royalty contract and other revenues' will reach $34.96 million. The estimate indicates a year-over-year change of +29.5%.
The collective assessment of analysts points to an estimated 'Total product sales- Total' of $7.30 billion. The estimate points to a change of +3.5% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- Oncology- Cell Therapy- Tecartus- U.S.' at $33.34 million. The estimate indicates a year-over-year change of -18.7%.
Based on the collective assessment of analysts, 'Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.' should arrive at $140.35 million. The estimate indicates a year-over-year change of -23.7%.
Analysts' assessment points toward 'Product Sales- Other- Other- U.S.' reaching $28.28 million. The estimate suggests a change of -35.7% year over year.
It is projected by analysts that the 'Product Sales- HIV- Genvoya- U.S.' will reach $252.74 million. The estimate indicates a year-over-year change of -21.5%.
Analysts forecast 'Product Sales- Total HIV- U.S.' to reach $4.38 billion. The estimate indicates a year-over-year change of +7%.
The combined assessment of analysts suggests that 'Product Sales- Liver Disease- Vemlidy- U.S.' will likely reach $121.18 million. The estimate indicates a change of -0.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Product Sales- Other- AmBisome- U.S.' should come in at $7.75 million. The estimate suggests a change of +10.7% year over year.
Analysts predict that the 'Product Sales- HIV- Other HIV- U.S.' will reach $40.24 million. The estimate suggests a change of -38.1% year over year.
Shares of Gilead have demonstrated returns of +5.4% over the past month compared to the Zacks S&P 500 composite's -1.5% change. With a Zacks Rank #3 (Hold), GILD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
The upcoming report from Gilead Sciences (GILD - Free Report) is expected to reveal quarterly loss of -$7.07 per share, indicating a decline of 451.7% compared to the year-ago period. Analysts forecast revenues of $7.37 billion, representing an increase of 4% year over year.
The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Gilead metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Product Sales- HIV- Genvoya- Total' to come in at $294.52 million. The estimate indicates a change of -21.9% from the prior-year quarter.
The consensus estimate for 'Product Sales- HIV- Descovy- Total' stands at $749.57 million. The estimate points to a change of +14.8% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Royalty contract and other revenues' will reach $34.96 million. The estimate indicates a year-over-year change of +29.5%.
The collective assessment of analysts points to an estimated 'Total product sales- Total' of $7.30 billion. The estimate points to a change of +3.5% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- Oncology- Cell Therapy- Tecartus- U.S.' at $33.34 million. The estimate indicates a year-over-year change of -18.7%.
Based on the collective assessment of analysts, 'Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.' should arrive at $140.35 million. The estimate indicates a year-over-year change of -23.7%.
Analysts' assessment points toward 'Product Sales- Other- Other- U.S.' reaching $28.28 million. The estimate suggests a change of -35.7% year over year.
It is projected by analysts that the 'Product Sales- HIV- Genvoya- U.S.' will reach $252.74 million. The estimate indicates a year-over-year change of -21.5%.
Analysts forecast 'Product Sales- Total HIV- U.S.' to reach $4.38 billion. The estimate indicates a year-over-year change of +7%.
The combined assessment of analysts suggests that 'Product Sales- Liver Disease- Vemlidy- U.S.' will likely reach $121.18 million. The estimate indicates a change of -0.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Product Sales- Other- AmBisome- U.S.' should come in at $7.75 million. The estimate suggests a change of +10.7% year over year.
Analysts predict that the 'Product Sales- HIV- Other HIV- U.S.' will reach $40.24 million. The estimate suggests a change of -38.1% year over year.
View all Key Company Metrics for Gilead here>>>Shares of Gilead have demonstrated returns of +5.4% over the past month compared to the Zacks S&P 500 composite's -1.5% change. With a Zacks Rank #3 (Hold), GILD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .